NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)

Blood

Volumn 106, Issue 12, 2005, Pages 3917-3925

  Kerbauy, Daniella M B ^a   Lesnikov, Vladimir ^a   Abbasi, Nissa ^a   Seal, Sudeshna ^a   Scott, Bart ^a   Joachim Deeg, H ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 8; CELL EXTRACT; ETANERCEPT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; TUMOR NECROSIS FACTOR ALPHA; X LINKED INHIBITOR OF APOPTOSIS; APOPTOSIS REGULATORY PROTEIN; CFLAR PROTEIN, HUMAN; GLUTATHIONE; GROWTH INHIBITOR; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOARSENIC DERIVATIVE; OXIDE; SIGNAL PEPTIDE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CD34 SELECTION; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MONONUCLEAR CELL; OBSERVATION; PRIORITY JOURNAL; PROTEIN INDUCTION; PURIFICATION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; UPREGULATION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; METABOLISM; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARSENICALS; BLOTTING, WESTERN; BONE MARROW CELLS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; FLOW CYTOMETRY; GLUTATHIONE; GROWTH INHIBITORS; HUMANS; IMMUNOGLOBULIN G; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; MYELODYSPLASTIC SYNDROMES; NF-KAPPA B; OXIDES; PROTEIN TRANSPORT; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28444479122     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1424     Document Type: Article

References (55)

1. Deeg HJ, Jiang PYZ, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res. 2004;28:1177-1180.
2. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965.
3. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429-2440.
4. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003;120:679-684.
5. Gersuk GM, Beckham C, Loken MR, et al. A role for tumor necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176-188.
6. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia. 1998;12:486-492.
7. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98:3058-3065.
8. Li X, Bryant E, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol. 2004;80:140-145.
9. Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res. 2003;27:583-591.
10. short in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia. 2003;17:2460-2466.
11. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kB and Erk signaling pathways. Curr Biol. 2000;10:640-648.
12. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol. 2001;21:5299-5305.
13. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Invest. 2001;107:241-246.
14. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
15. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kB transcription factors. Oncogene. 1999;18:6910-6924.
16. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kB and its significance in prostate cancer. Oncogene. 2001;20:7342-7351.
17. Chu Z-L, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kb control. Proc Natl Acad Sci U S A. 1997;94:10057-10062.
18. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kb activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861-1874.
19. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307.
20. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
21. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
22. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181-190.
23. Beg AA, Baltimore D. An essential role for NF-kb in preventing TNF-a-induced cell death. Science. 1996;274:782-784.
24. List A, Beran M, DiPersio J, et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 2003;17:1499-1507.
25. List AF, Schiller GJ, Mason J, Douer D, Ellison R. Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase 2 clinical study [abstract]. Blood. 2003;102:423a.
26. Vey N, Dreyfus F, Guerci A, et al. Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary results of a phase 1/2 study [abstract]. Blood. 2003;102:422a.
27. Estrov Z, Manna SK, Harris D, et al. Phenylarsine oxide blocks interleukin-1b-induced activation of the nuclear transcription factor NF-kB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999;94:2844-2853.
28. Park JW, Choi YJ, Jang MA, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun. 2001;286:726-734.
29. Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60:3065-3071.
30. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-a-triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-kB activation. Blood. 2000;96:2849-2855.
31. Hu W-H, Johnson H, Shu H-B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kb and JNK activation and apoptosis through distinct pathways. J Biol Chem. 1999;274:30603-30610.
32. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-kB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 2005;105:804-811.
33. + bone marrow cell survival. Blood. 1999;93:3302-3308.
34. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood. 2003;102:394-403.
35. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin K-M, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kb. Oncogene. 2003;22:3842-3852.
36. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049-2054.
37. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kB activity. Leukemia. 2001;15:921-928.
38. Vinante F, Rigo A, Tecchio C, et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol. 1998;102:1025-1034.
39. Kasahara S, Hara T, Itoh H, et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. Br J Haematol. 2002;118:181-188.
40. Reddy SAG, Huang JH, Liao WSL. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-kB activation. J Immunol. 2000;164:1355-1363.
41. Gustin JA, Ozes ON, Akca H, et al. Cell type-specific expression of the IkB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-k B activation. J Biol Chem. 2004;279:1615-1620.
42. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-kB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia. 2004;18: 103-112.
43. Meng F, D'Mello SR. NF-kB stimulates Akt phosphorylation and gene expression by distinct signaling mechanisms. Biochim Biophys Acta. 2003;1630:35-40.
44. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kB-dependent transcription in mice. J Biol Chem. 2003;278:1450-1456.
45. Mak NK, Wong RN, Leung KN, Fung M. Involvement of tumor necrosis factor (TNF-a) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells. Toxicology Letters. 2002;135:79-87.
46. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF- kB signaling pathway. Mol Cell Biol. 2004;24:2627- 2636.
47. Davison K, Côté S, Mader S, Miller WH, Jr.. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia. 2003;17:931-940.
48. Yang C-H, Kuo M-L, Chen J-C, Chen Y-C. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer. 1999;81:796-799.
49. Mundle SD, Venugopal P, Cartlidge JD, et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996;88:2640-2647.
50. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932-3938.
51. Yamamoto K, Abe S, Nakagawa Y, et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res. 2004;28:1203-1211.
52. Sanz C, Richard C, Prosper F, Fernandez-Luna JL. Nuclear factor k B is activated in myelodysplastic bone marrow cells. Haematologica. 2002;87:1005- 1006.
53. Bueso-Ramos CE, Rocha FC, Shishodia S, et al. Expression of constitutively active nuclear-kB RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004;35:246-253.
54. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20:891-900.
55. Ramos AM, Fernández C, Amrán D, Sancho P, de Blas E, Alter P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood. 2005;105:4013-4020.